Neurocrine director granted options and RSUs

NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk received new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk received new equity awards. On May 27, 2026, Norwalk was granted 2,624 non-qualified stock options for common stock with an exercise price of $155.83 per share, expiring on May 27, 2036. These options vest in 12 monthly installments beginning on June 27, 2026.

Norwalk was also granted 1,284 Restricted Stock Units (RSUs), each representing the right to receive one share of common stock upon vesting. The RSUs will vest in full on May 27, 2027. These awards are compensation-related grants rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 3,908 shares

Grant/Award 2 txns

Insider Norwalk Leslie V

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restriced Stock Unit	1,284	$0.00	$0.00
Grant/Award	Non-Qualified Stock Option	2,624	$0.00	$0.00

Holdings After Transaction: Restriced Stock Unit — 1,284 contracts (Direct); Non-Qualified Stock Option — 2,624 contracts (Direct)

Footnotes (3)

F1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2. The RSUs will vest in full on May 27, 2027.
F3. Option vests in 12 monthly installments beginning June 27, 2026.

Key Figures

Stock options granted: 2,624 options Option exercise price: $155.83/share Option expiration: May 27, 2036 +5 more

8 metrics

Stock options granted 2,624 options Non-qualified stock option grant on May 27, 2026

Option exercise price $155.83/share Exercise price for 2,624 non-qualified stock options

Option expiration May 27, 2036 Expiration date of non-qualified stock options

RSUs granted 1,284 RSUs Restricted Stock Unit award on May 27, 2026

RSU vesting date May 27, 2027 RSUs vest in full on this date

Option vesting schedule 12 monthly installments Vesting begins June 27, 2026

Options held after grant 2,624 options Total non-qualified stock options following transaction

RSUs held after grant 1,284 RSUs Total Restricted Stock Units following transaction

Key Terms

Non-Qualified Stock Option, Restricted Stock Unit ("RSU"), exercise price, vesting, +1 more

5 terms

Non-Qualified Stock Option financial

"security_title: "Non-Qualified Stock Option""

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Restricted Stock Unit ("RSU") financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share"

exercise price financial

"conversion_or_exercise_price": "155.8300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The RSUs will vest in full on May 27, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date": "2036-05-27T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did NBIX director Leslie V. Norwalk receive?

Leslie V. Norwalk received 2,624 non-qualified stock options and 1,284 Restricted Stock Units from Neurocrine Biosciences. The options carry a set exercise price, while each RSU represents one future share of common stock upon vesting, reflecting equity-based director compensation.

When do Leslie V. Norwalk’s new NBIX stock options vest?

The 2,624 non-qualified stock options vest in 12 monthly installments beginning June 27, 2026. This monthly vesting spreads the award over one year, aligning option availability with continued board service during that period at Neurocrine Biosciences.

When will Leslie V. Norwalk’s NBIX Restricted Stock Units vest?

Norwalk’s 1,284 Restricted Stock Units will vest in full on May 27, 2027. Upon vesting, each RSU converts into one share of Neurocrine Biosciences common stock, providing the director with additional direct equity ownership at that time.

What is the exercise price and expiration date of the NBIX options granted?

The non-qualified stock options have an exercise price of $155.83 per share and expire on May 27, 2036. This gives Leslie V. Norwalk a long-term window to decide whether to exercise the options, depending on future share price performance.

Are Leslie V. Norwalk’s NBIX Form 4 transactions open-market buys or sells?

No, the Form 4 shows grant or award acquisitions, not open-market buys or sells. The transactions are coded as awards of options and RSUs to Leslie V. Norwalk as part of compensation, with no reported market purchases or sales of existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/29/2026 - 06:01 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norwalk Leslie V

(Last)

(First)

(Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restriced Stock Unit⁽¹⁾	$0	05/27/2026		A		1,284		⁽²⁾	⁽²⁾	Common Stock	1,284	$0	1,284	D
Non-Qualified Stock Option	$155.83	05/27/2026		A		2,624		⁽³⁾	05/27/2036	Common Stock	2,624	$0	2,624	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. The RSUs will vest in full on May 27, 2027.

3. Option vests in 12 monthly installments beginning June 27, 2026.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR